Meta-analysis of clinical trials to assess denosumab over zoledronic acid in bone metastasis
Conclusion Overall, denosumab showed superiority in delaying the first and subsequent SREs, and hence seems to be a promising choice for managing bone metastases in both solid tumors and MM. However, it can induce a higher incidence of ONJ and hypocalcaemia, but these are preventable and manageable effects.
Source: International Journal of Clinical Pharmacy - Category: Drugs & Pharmacology Source Type: research
More News: Clinical Trials | Databases & Libraries | Drugs & Pharmacology | Healthcare Costs | Hypocalcaemia | Myeloma | Pain | Reclast | Science | Study | Toxicology | Xgeva | Zometa